Premium
Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas
Author(s) -
AlHalabi Hani,
Montes José L.,
Atkinson Jeffrey,
Farmer JeanPierre,
Freeman Carolyn R.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22614
Subject(s) - medicine , adjuvant radiotherapy , adjuvant , surgery , radiation therapy , ependymoma , lumbosacral joint , oncology
Objectives Assess the role of radiotherapy (RT) in the management of primary and recurrent myxopapillary ependymoma (MPE). Materials and Methods We conducted a retrospective review of patients with MPE treated at the Montreal Children's Hospital/McGill University Health Centre between 1985 and 2008. Results Seven children under the age of 18 were diagnosed and treated for MPE. All patients were treated with surgery to the primary site. Three patients underwent subtotal resection (STR) and received adjuvant post‐operative RT. Only one patient who had spinal drop metastases received post‐operative RT to the lumbosacral region following complete resection of the primary tumor. After a median follow up of 78 months (range 24–180 months), all patients were alive with controlled disease. The single patient treated with gross total resection (GTR) and adjuvant local radiation remained recurrence free. One of the three patients treated with STR and adjuvant RT had disease progression that was controlled with re‐resection and further RT. Two of the three patients treated with surgery alone developed local and disseminated recurrent spinal disease that was controlled by salvage RT. Conclusion Our data support the evolving literature which suggests that GTR alone provides suboptimal disease control in MPE. In our patients, RT resulted in control of residual, metastatic and/or recurrent disease. Routine adjuvant RT may improve outcomes in pediatric MPE. Pediatr Blood Cancer. 2010;55:639–643. © 2010 Wiley‐Liss, Inc.